Durvalumab
D9072C00001
Phase 3 small_molecule active
Quick answer
Durvalumab for Non-Small Cell Lung Cancer is a Phase 3 program (small_molecule) at AstraZeneca with 2 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca
- Indication
- Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active